Liquidia (LQDA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 16, 2026, to be held virtually at 4:30 p.m. Eastern Time.
Proxy materials and 2025 annual report are available online for review and voting.
Shareholders are encouraged to review all proxy materials before voting and can opt for electronic delivery.
Voting matters and shareholder proposals
Election of three directors: David Johnson, Katie Rielly-Gauvin, and Ramandeep Singh, with board recommending a vote FOR all nominees.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
Advisory approval of named executive officer compensation, with board recommending a vote FOR.
Board of directors and corporate governance
Board provides recommendations on all voting matters and nominees for director positions.
Latest events from Liquidia
- Record-breaking YUTREPIA launch fuels growth, with key votes on directors, auditor, and pay.LQDA
Proxy filing24 Apr 2026 - Strong commercial uptake, expanding clinical programs, and profitability support a $1B revenue goal by 2027.LQDA
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Rapid launch and profitability drive $148.3M sales and 17% Q4 market share in 2025.LQDA
Q4 20255 Mar 2026 - Yutrepia and L606 advance inhaled treprostinil with strong data, FDA approval, and global expansion.LQDA
R&D Day 20253 Feb 2026 - Q2 loss widened as revenue fell; legal wins clear path for FDA approval, but funding needs persist.LQDA
Q2 20242 Feb 2026 - YUTREPIA awaits final FDA approval, with launch readiness and a strong clinical and legal position.LQDA
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Yutrepia targets a major Q2 2025 launch in PAH and PH-ILD, with strong market and legal positioning.LQDA
2024 Wells Fargo Healthcare Conference22 Jan 2026 - YUTREPIA targets a major 2025 launch, with robust pipeline, legal, and financial strategies in place.LQDA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Rapid profitability and 25% market share achieved, fueling breakout growth in pulmonary care.LQDA
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026